<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118074</url>
  </required_header>
  <id_info>
    <org_study_id>NB21-eGFR-NA-FDA</org_study_id>
    <nct_id>NCT05118074</nct_id>
  </id_info>
  <brief_title>Nova Max Creatinine and eGFR Meter System</brief_title>
  <official_title>Nova Max Creatinine and eGFR Meter System - Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Biomedical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>South Florida Research Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charisma Medical and Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Excellence Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Biomedical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of&#xD;
      CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical&#xD;
      settings on venous, and capillary blood and compare the performance characteristics to a&#xD;
      traceable laboratory reference method (the Siemens EXL creatinine determination).&#xD;
&#xD;
      To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of&#xD;
      the intended CLIA-Waived Point-of-Care users.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to evaluate the performance of the NM Meter when used by CLIAW&#xD;
      operators in terms of both accuracy to an established reference method and precision. CLIAW&#xD;
      operators will receive no training or prompting on how to use the NM Creatinine and eGFR&#xD;
      Meter, operating only using the instructions found in printed labeling materials (IFU, QRG,&#xD;
      packaging).&#xD;
&#xD;
      In determining the accuracy of the device, subjects will be tested using the NM Creatinine&#xD;
      and eGFR Meter alongside a central laboratory reference method and the results will be&#xD;
      compared to one another. This portion of the study is referred to as Method Comparison.&#xD;
&#xD;
      In determining the precision of the device, multiple creatinine determinations will be made&#xD;
      with the NM Creatinine and eGFR meter using both stabilized control materials (testing over&#xD;
      the course of 20 days) and venous whole blood specimens (tested over the course of a single&#xD;
      day). The difference between the multiple test results will determine the device's level of&#xD;
      precision. This portion of the study is referred to as Precision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analytical verification of Nova Max creatinine and eGFR meter system - Creatinine comparison</measure>
    <time_frame>20 days</time_frame>
    <description>Nova Max creatinine and eGFR meter system, a point of care testing instrument is as effective as a reference laboratory method for Creatinine blood results in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analytical verification of Nova Max creatinine and eGFR meter system - eGFR comparison</measure>
    <time_frame>20 days</time_frame>
    <description>Nova Max creatinine and eGFR meter system, a point of care testing instrument is as effective as a reference laboratory method for eGFR blood results in mL/min/1.73 m^2</description>
  </primary_outcome>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <condition>Acute Kidney Injury</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Creatinine, eGFR</intervention_name>
    <description>Compare diagnostic tests to reference methods</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be identified via medical records for history of CKD or compromised kidney&#xD;
        function and contacted to participate in this study. Study site personnel will provide&#xD;
        details regarding the study (requirements, test procedure, subject rights) to obtain&#xD;
        informed consent from the subject.&#xD;
&#xD;
        Potential subjects will be screened using the protocol inclusion and/or exclusion criteria.&#xD;
        Adult subjects (≥ 18 years of age) with creatinine levels spanning the entire AMR of the NM&#xD;
        Creatinine and eGFR Meter will be recruited for the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult males or females (≥ 18 years of age)&#xD;
&#xD;
          2. CKD Stage 1 (healthy)&#xD;
&#xD;
          3. CKD Stages 2-4&#xD;
&#xD;
          4. Subjects willing and able to consent to participating in the study.&#xD;
&#xD;
          5. Subjects whose pre-screen creatinine and eGFR value, if performed, is deemed valuable&#xD;
             to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects unable to consent to participating in the study.&#xD;
&#xD;
          2. Subjects possessing a cognitive disorder or other condition, which, in the opinion of&#xD;
             the investigator, would put the person at risk or seriously compromise the integrity&#xD;
             of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giralt Yanez</last_name>
    <role>Principal Investigator</role>
    <affiliation>South Florida Research Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Alvarez</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charisma Medical and Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeremy Bleicher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Excellence Medical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarrid Legere, Bachelor</last_name>
    <phone>781-894-0800</phone>
    <phone_ext>1801</phone_ext>
    <email>jlegere@novabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Qiu, MD, PhD</last_name>
    <phone>781-894-0800</phone>
    <phone_ext>1715</phone_ext>
    <email>wqiu@novabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South Florida Research Organization</name>
      <address>
        <city>Medley</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Valdes</last_name>
      <phone>305-450-5308</phone>
      <email>cvaldes@sfrotrials.com</email>
    </contact>
    <investigator>
      <last_name>Giralt Yanez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Excellence Medical Research</name>
      <address>
        <city>Miami Gardens</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Martinez</last_name>
      <phone>786-205-8666</phone>
      <email>amartinez@emrclinic.com</email>
    </contact>
    <investigator>
      <last_name>Jeremy Bleicher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charisma Medical and Research Center</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Valdes</last_name>
      <phone>305-450-5308</phone>
      <email>cvaldes@sfrotrials.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>eGFR</keyword>
  <keyword>Creatinine</keyword>
  <keyword>POCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

